Ipca Labs

Ipca Laboratories on Thursday said its consolidated net profit declined 58 per cent year-on-year to Rs 229 crore in the September quarter. The drug firm had reported a net profit of Rs 145 crore in the year-ago period. Revenue from operations rose to Rs 2,355 crore for the second quarter of the current fiscal year as compared with Rs 2,034 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The company said its domestic formulations business revenue stood at Rs 940 crore for the quarter, up 11 per cent from Rs 845 crore a year earlier. Export of generics stood at Rs 286 crore in the July-September period as against Rs 264 crore, registering a year-on-year growth of 8 per cent. The company said its board has approved an interim dividend of Rs 21 per share of Re 1 each for 2024-25. Shares of the company on Thursday ended 2.02 per cent up at Rs 1,538.65 apiece on the BSE.

Unichem Labs share price: Unichem Laboratories' board has approved asset purchase agreement with Bayshore Pharmaceuticals

Ipca laboratories share price surged up to 3.66 per cent intraday, hitting their all time high at Rs 1509.45 per share on the BSE

This drug has shown a 77.20 per cent ulcer closure rate in clinical trials, offering hope for a condition that often leads to severe outcomes like lower limb amputations

Shares of Ipca Labs slipped 2.82 per cent to Rs 1312.55 per share on the BSE in Friday's early morning trade

Ipca Laboratories on Tuesday said its consolidated net profit increased 18 per cent to Rs 192 crore for the first quarter ended June 30, 2024 aided by robust sales in the domestic market. The drug firm had reported a net profit of Rs 163 crore for the April-June period of last fiscal. Revenue from operations rose to Rs 2,093 crore for the April-June quarter, as compared to Rs 1,585 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. The drug firm said domestic formulations income rose 12 per cent year-on-year to Rs 873 crore in the first quarter. Exports income, however, declined 4 per cent year-on-year to Rs 591 crore during the June quarter, the company said. Shares of Ipca Laboratories on Tuesday closed 1.33 per cent up at Rs 1,400 apiece on the BSE.

Hindustan Unilever is in overall uptrend and is on the verge of giving Pole and Flag pattern breakout on daily chart

The uptick in share price came after the company announced that the EU Court upheld Rs 126 crore fine imposed on Ipca Labs' unit, Unichem Laboratories

Ipca Laboratories on Wednesday reported 67 per cent increase in consolidated net profit at Rs 180 crore for the third quarter ended December 31, 2023. The drugmaker had reported a net profit of Rs 108 crore for October-December FY23. Revenue from operations rose to Rs 2,053 crore from Rs 1,546 crore in the year-ago period, Ipca Laboratories said in a regulatory filing. Shares of the company were trading 0.86 per cent down at Rs 1,150.15 apiece on the BSE.

Ipca Laboratories on Wednesday said it has completed the acquisition of a 33.38 per cent stake in Unichem for Rs 945.35 crore. Last week, Ipca got approval from the Competition Commission of India (CCI) for a 59.38 per cent stake purchase in listed Unichem Laboratories. "Post receipt of approval of CCI, the company has acquired 2,35,01,440 fully paid-up equity shares of Rs 2 each, constituting about 33.38 per cent of the paid-up equity share capital of Unichem Laboratories from one of Unichem's promoter shareholders, at a price of Rs 402.25 per equity share aggregating to Rs 945.35 crore," Ipca said in a regulatory filing. The deal was executed through a block deal on the National Stock Exchange (NSE), it added. Ipca has already made an open offer to Unichem's shareholders to acquire another 26 per cent of the fully diluted outstanding equity share capital of the company at a price of Rs 440 per share, aggregating to Rs 805.44 crore. The Draft Letter of Offer (DLOF) for the open o

Stocks to Watch on June 26, 2023: The Hinduja Group is in talks to invest Rs 10,000 crore to hike its stake in IndusInd Bank, as per media reports

Company says it takes quality and compliance issues with 'utmost importance'

Stocks to Watch today, June 5, 2023: Brent crude related stocks could see considerable action today as oil prices jumped over 2 per cent overnight, and another 2 per cent Monday morning

The acquisition will allow Ipca to re-enter US formulation generic market, however at 2.3x sales, as acquisition cost is expensive, given challenges and uncertainty associated with US market.

Unichem's facilities are compliant with US regulations, but it posted losses for nine months of FY23

Brokerages believe the acquisition is expensive, given increased competition in the US generics oral solids space, rising regulatory risks and strong efforts needed to turnaround Unichem Labs

The acquisition is subject to the fulfilment of terms and conditions as per the share purchase agreement, and statutory approvals from the Competition Commission of India, the company added

In Q3, Ipca's operating profit margin was lowest since FY19, impacted by lower gross margins, and continued higher overheads.

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

The world's race for a coronavirus drug hinges on Indian companies working with their global peers. Business Standard tracks six companies to feel the pulse of Indian pharma